NCT03412305

Brief Summary

The overall aim of the study is to investigate whether routine administration of antibiotic prophylaxis 1 hour prior to implant surgery may prevent postoperative infection and implant loss in healthy or substantially healthy patients (ASA Class 1 and Class 2).

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
474

participants targeted

Target at P75+ for phase_4

Timeline
Completed

Started Jan 2014

Longer than P75 for phase_4

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2014

Completed
4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2017

Completed
19 days until next milestone

First Submitted

Initial submission to the registry

January 19, 2018

Completed
7 days until next milestone

First Posted

Study publicly available on registry

January 26, 2018

Completed
3.5 years until next milestone

Study Completion

Last participant's last visit for all outcomes

August 10, 2021

Completed
Last Updated

August 25, 2021

Status Verified

August 1, 2021

Enrollment Period

4 years

First QC Date

January 19, 2018

Last Update Submit

August 19, 2021

Conditions

Keywords

Dental implants, antibiotic prophylaxis

Outcome Measures

Primary Outcomes (1)

  • Implant failure

    Early implant mobility and/or infection, which requires the implant to be removed.

    3-6 months after implant placement

Secondary Outcomes (2)

  • Postoperative infection

    7-14 days after implant placement

  • Infection

    3-6 months after implant placement

Study Arms (2)

Amoxicillin oral tablets

ACTIVE COMPARATOR

2 g amoxicillin tablets orally 1 hour before implant placement

Drug: Amoxicillin

Placebo

PLACEBO COMPARATOR

Placebo tablets orally 1 hour before implant placement

Other: Placebo

Interventions

Antibiotic prophylaxis consisting of 4 amoxicillin tablets, totally 2 g, orally 1 hour before implant placement

Also known as: Amoxicillin oral tablets
Amoxicillin oral tablets
PlaceboOTHER

Placebo consisting of 4 tablets, orally 1 hour before implant placement

Also known as: Placebo oral tablets (for Amoxicillin)
Placebo

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Requirement for dental implant placement
  • Over 18 years of age

You may not qualify if:

  • Immunosuppressed or immunocompromised
  • Affected by not controlled diabetes
  • Serious or severe systemic disease (ASA classification \> 2)
  • Previous radiotherapy to the head or neck area
  • Ongoing acute or chronic infection in the oral cavity
  • Ongoing treatment with antibiotics
  • Hypersensitivity to penicillin
  • Previous or ongoing treatment with bisphosphonates
  • In need of major bone augmentation
  • Planned direct loading or early loading (within 2 weeks) of the implant

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Malmö university

Malmo, 20506, Sweden

Location

Related Publications (1)

  • Momand P, Becktor JP, Naimi-Akbar A, Tobin G, Gotrick B. Effect of antibiotic prophylaxis in dental implant surgery: A multicenter placebo-controlled double-blinded randomized clinical trial. Clin Implant Dent Relat Res. 2022 Feb;24(1):116-124. doi: 10.1111/cid.13068. Epub 2022 Jan 24.

MeSH Terms

Interventions

Amoxicillin

Intervention Hierarchy (Ancestors)

AmpicillinPenicillin GPenicillinsbeta-LactamsLactamsAmidesOrganic ChemicalsSulfur CompoundsHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingHeterocyclic Compounds

Study Officials

  • Bengt Götrick

    Malmö University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Masking Details
The tablets corresponding to each patient is packed in a container by the manufacturer of the trial drug. Each drug container is labeled by a code number (1-1000) and the contents of the containers are distributed according to a randomization list with block size 6. Randomization is thus carried out by the manufacturer, independent of investigator and participating clinicians.
Purpose
PREVENTION
Intervention Model
PARALLEL
Model Details: Randomized, placebo-controlled trial
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
associate professor

Study Record Dates

First Submitted

January 19, 2018

First Posted

January 26, 2018

Study Start

January 1, 2014

Primary Completion

December 31, 2017

Study Completion

August 10, 2021

Last Updated

August 25, 2021

Record last verified: 2021-08

Data Sharing

IPD Sharing
Will not share

Locations